News & Updates

HEART-FID confirms IV iron safety for HF but falls short in efficacy
HEART-FID confirms IV iron safety for HF but falls short in efficacy
11 Sep 2023 byAudrey Abella

The HEART-FID trial narrowly missed its primary endpoint, showing modest improvement in all-cause mortality, heart failure hospitalizations (hHF), and exercise function with ferric carboxymaltose (FCM) in HFrEF* patients with iron deficiency (ID).

HEART-FID confirms IV iron safety for HF but falls short in efficacy
11 Sep 2023
Primary PCI strategy reduces death rates in STEMI patients
Primary PCI strategy reduces death rates in STEMI patients
09 Sep 2023

Between 2003 and 2018, 1-year mortality has decreased considerably in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) in a high-income European country with a fully implemented primary PCI strategy, reports a study.

Primary PCI strategy reduces death rates in STEMI patients
09 Sep 2023
Dapagliflozin safe, effective in HF patients across global regions
Dapagliflozin safe, effective in HF patients across global regions
08 Sep 2023 byStephen Padilla

Dapagliflozin for individuals with heart failure (HF) demonstrates consistent safety and efficacy across regions worldwide despite geographic differences in patient characteristics, background treatment, and event rates, reports a recent study.

Dapagliflozin safe, effective in HF patients across global regions
08 Sep 2023
Depression ups risk of CVD, mortality
Depression ups risk of CVD, mortality
08 Sep 2023 byStephen Padilla

Individuals with depression are at higher risk of developing cardiovascular disease (CVD), which may even result in death, suggests a recent study.

Depression ups risk of CVD, mortality
08 Sep 2023